Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Accumulated Expenses (2016 - 2025)

Anaptysbio filings provide 10 years of Accumulated Expenses readings, the most recent being $11.1 million for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses rose 31.31% year-over-year to $11.1 million, compared with a TTM value of $11.1 million through Dec 2025, up 31.31%, and an annual FY2025 reading of $11.1 million, up 31.31% over the prior year.
  • Accumulated Expenses hit $11.1 million in Q4 2025 for Anaptysbio, down from $33.2 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $38.4 million in Q3 2024, with the low at $8.4 million in Q4 2024.
  • Median Accumulated Expenses over the past 5 years was $23.8 million (2022), compared with a mean of $23.5 million.
  • The sharpest move saw Accumulated Expenses soared 110.39% in 2023, then plummeted 72.72% in 2024.
  • Year by year, Accumulated Expenses stood at $12.9 million in 2021, then soared by 68.31% to $21.6 million in 2022, then skyrocketed by 43.15% to $31.0 million in 2023, then crashed by 72.72% to $8.4 million in 2024, then soared by 31.31% to $11.1 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $11.1 million, $33.2 million, and $30.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.